BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19026650)

  • 1. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay.
    Zou H; Taylor WR; Harrington JJ; Hussain FT; Cao X; Loprinzi CL; Levine TR; Rex DK; Ahnen D; Knigge KL; Lance P; Jiang X; Smith DI; Ahlquist DA
    Gastroenterology; 2009 Feb; 136(2):459-70. PubMed ID: 19026650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
    Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
    Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget stool DNA testing for colorectal-cancer screening.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
    N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stool DNA and occult blood testing for screen detection of colorectal neoplasia.
    Ahlquist DA; Sargent DJ; Loprinzi CL; Levin TR; Rex DK; Ahnen DJ; Knigge K; Lance MP; Burgart LJ; Hamilton SR; Allison JE; Lawson MJ; Devens ME; Harrington JJ; Hillman SL
    Ann Intern Med; 2008 Oct; 149(7):441-50, W81. PubMed ID: 18838724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly methylated genes in colorectal neoplasia: implications for screening.
    Zou H; Harrington JJ; Shire AM; Rego RL; Wang L; Campbell ME; Oberg AL; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2686-96. PubMed ID: 18086775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.
    Tagore KS; Lawson MJ; Yucaitis JA; Gage R; Orr T; Shuber AP; Ross ME
    Clin Colorectal Cancer; 2003 May; 3(1):47-53. PubMed ID: 12777192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of APC mutations in fecal DNA from patients with colorectal tumors.
    Traverso G; Shuber A; Levin B; Johnson C; Olsson L; Schoetz DJ; Hamilton SR; Boynton K; Kinzler KW; Vogelstein B
    N Engl J Med; 2002 Jan; 346(5):311-20. PubMed ID: 11821507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.
    Ahlquist DA; Zou H; Domanico M; Mahoney DW; Yab TC; Taylor WR; Butz ML; Thibodeau SN; Rabeneck L; Paszat LF; Kinzler KW; Vogelstein B; Bjerregaard NC; Laurberg S; Sørensen HT; Berger BM; Lidgard GP
    Gastroenterology; 2012 Feb; 142(2):248-56; quiz e25-6. PubMed ID: 22062357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
    O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
    Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.
    Bosch LJ; Oort FA; Neerincx M; Khalid-de Bakker CA; Terhaar sive Droste JS; Melotte V; Jonkers DM; Masclee AA; Mongera S; Grooteclaes M; Louwagie J; van Criekinge W; Coupé VM; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cancer Prev Res (Phila); 2012 Mar; 5(3):464-72. PubMed ID: 22135045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening.
    Chen J; Lin J; Zhang L; Chen M; Yu X; Wu Y; Wang T; Xu R; Tian T; Sun A; Zhang T; Lu Y; Ba Z; Cheng X; Chen M
    Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population.
    Suehiro Y; Sakai K; Nishioka M; Hashimoto S; Takami T; Higaki S; Shindo Y; Hazama S; Oka M; Nagano H; Sakaida I; Yamasaki T
    Ann Clin Biochem; 2017 Jan; 54(1):86-91. PubMed ID: 27126270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
    Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.
    Bosch LJ; Mongera S; Terhaar Sive Droste JS; Oort FA; van Turenhout ST; Penning MT; Louwagie J; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cell Oncol (Dordr); 2012 Aug; 35(4):309-15. PubMed ID: 22821210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting colorectal cancer in stool with the use of multiple genetic targets.
    Dong SM; Traverso G; Johnson C; Geng L; Favis R; Boynton K; Hibi K; Goodman SN; D'Allessio M; Paty P; Hamilton SR; Sidransky D; Barany F; Levin B; Shuber A; Kinzler KW; Vogelstein B; Jen J
    J Natl Cancer Inst; 2001 Jun; 93(11):858-65. PubMed ID: 11390535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.